Addex Therapeutics (ADXN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed May 15, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ADXN SEC filings page.
Addex Therapeutics Ltd (ADXN) reported $218K in revenue for fiscal year 2025, down 51.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).
The latest filing reports $5M of revenue but no earnings, cash-flow, or balance-sheet figures, leaving the business's financial mechanics unclear.
The available figures do not establish whether revenue reflects recurring operations, licensing, or another source, because profitability, cash generation, and financing data are absent.
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
We do not publish a peer-relative financial health score for Addex Therapeutics Ltd, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Addex Therapeutics Ltd scores -79.04, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $453.7M against total assets of $8.0M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Addex Therapeutics Ltd passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.
Addex Therapeutics Ltd reported a net loss of $8.5M while operations used $2.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Addex Therapeutics Ltd reported an operating loss of $3.5M against $614 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Addex Therapeutics Ltd generated $218K in revenue in fiscal year 2025. This represents a decrease of 51.8% from the prior year.
Addex Therapeutics Ltd reported a net loss of $8.5M in fiscal year 2025. This represents a decrease of 209.0% from the prior year.
Addex Therapeutics Ltd earned -$0.08 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 197.9% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Addex Therapeutics Ltd recorded an outflow of $2.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Addex Therapeutics Ltd held $2.1M in cash against $0 in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Addex Therapeutics Ltd's ROE was -141.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 214.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Addex Therapeutics Ltd invested $846K in research and development in fiscal year 2025. This represents a decrease of 10.2% from the prior year.
Addex Therapeutics Ltd reported no capital expenditure in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Not reported for fiscal year 2025.
ADXN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218K-51.8% | $452K-76.5% | $1.9M+23.1% | $1.6M-54.6% | $3.4M-21.4% | $4.4M+49.8% | $2.9M-57.0% | $6.8M+1228.0% | $513K |
| R&D Expenses | $846K-10.2% | $942K-33.3% | $1.4M-84.2% | $8.9M-36.5% | $14.0M+19.7% | $11.7M-8.8% | $12.9M+157.2% | $5.0M+85.3% | $2.7M |
| Operating Income | -$3.5Mn/m | -$3.0Mn/m | -$2.7Mn/m | -$11.4Mn/m | -$17.0Mn/m | -$13.8Mn/m | -$15.1Mn/m | -$1.4Mn/m | -$3.3M |
| Interest Expense | $614-65.4% | $2K-9.3% | $2K-12.6% | $2K-94.8% | $43K-25.0% | $57K-47.9% | $109K-19.9% | $137K+77691.2% | $176 |
| Income Tax | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | N/A |
| Net Income | -$8.5M-209.0% | $7.8Mn/m | -$12.6Mn/m | -$22.5Mn/m | -$16.8Mn/m | -$14.5Mn/m | -$15.3Mn/m | -$1.7Mn/m | -$3.4M |
| EPS (Basic) | -$0.08-197.9% | $0.08n/m | -$0.17 | -$0.50 | -$0.49n/m | -$0.54n/m | -$0.58 | N/A | N/A |
| EPS (Diluted) | -$0.08-197.9% | $0.08n/m | -$0.17 | -$0.50 | -$0.49n/m | -$0.54n/m | -$0.58 | N/A | N/A |
| Diluted Shares (Avg) | 107M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, SG&A Expenses, EBITDA.
ADXN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.0M-31.9% | $11.8M+113.2% | $5.5M-38.4% | $9.0M-63.6% | $24.6M+8.0% | $22.8M-33.1% | $34.1M-20.5% | $42.9M | N/A |
| Current Assets | $2.1M-45.8% | $3.9M-22.5% | $5.0M-40.5% | $8.5M-64.7% | $24.0M+8.8% | $22.0M-34.1% | $33.5M-21.9% | $42.9M | N/A |
| Cash & Equivalents | $2.1M-44.0% | $3.7M-19.9% | $4.6M-38.9% | $7.5M-66.4% | $22.4M+5.9% | $21.1M-35.1% | $32.6M+1.6% | $32.1M+1111.0% | $2.6M |
| Accounts Receivable | $25K+48.0% | $17K-87.0% | $131K-70.9% | $451K+150.4% | $180K+133.0% | $77K-36.6% | $122K-56.1% | $278K | N/A |
| Total Liabilities | $2.0M+82.4% | $1.1M-73.5% | $4.2M+14.1% | $3.6M-40.6% | $6.1M-2.7% | $6.3M-18.7% | $7.8M+156.5% | $3.0M | N/A |
| Current Liabilities | $1.5M+70.8% | $885K-74.3% | $3.4M-3.1% | $3.6M-21.4% | $4.5M+10.4% | $4.1M-30.2% | $5.9M+147.3% | $2.4M | N/A |
| Non-Current Liabilities | $502K+129.0% | $219K-69.4% | $718K+662.0% | $94K-94.2% | $1.6M-26.9% | $2.2M+17.1% | $1.9M+189.9% | $650K | N/A |
| Long-Term Debt | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | N/A |
| Total Equity | $6.0M-43.7% | $10.7M+683.1% | $1.4M-74.4% | $5.3M-71.3% | $18.5M+12.0% | $16.5M-37.3% | $26.4M-33.9% | $39.9M+2795.0% | $1.4M |
| Retained Earnings | -$453.7Mn/m | -$389.7Mn/m | -$428.8Mn/m | -$378.6Mn/m | -$359.8Mn/m | -$354.8Mn/m | -$310.9Mn/m | -$291.0M | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill.
ADXN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.7Mn/m | -$5.9Mn/m | -$9.5Mn/m | -$17.8Mn/m | -$16.1Mn/m | -$13.8Mn/m | -$9.8M-650.0% | $1.8Mn/m | -$2.2M |
| Capital Expenditures | $0-100.0% | $1K-82.8% | $8K+1194.8% | $629-98.2% | $34K-48.7% | $67K+128.5% | $29K+219.4% | $9K+1186.6% | $716 |
| Free Cash Flow | -$2.7Mn/m | -$5.9Mn/m | -$9.5Mn/m | -$17.8Mn/m | -$16.1Mn/m | -$13.8Mn/m | -$9.8M-654.5% | $1.8Mn/m | -$2.2M |
| Investing Cash Flow | -$858K-116.7% | $5.1Mn/m | -$8K-353.1% | $3Kn/m | -$33Kn/m | -$67Kn/m | -$45Kn/m | -$57Kn/m | -$716 |
| Financing Cash Flow | $1.5M+1189.3% | $116K-98.2% | $6.3M+86.6% | $3.4M-81.3% | $17.9M+34072.8% | $52Kn/m | -$479K-101.3% | $38.0M+1003.7% | $3.4M |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.
ADXN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1628.3% | -671.9% | -138.7% | -729.5% | -491.7% | -315.6% | -515.4% | -21.3% | -647.1% |
| Net Margin | -3892.3% | 1720.7% | -652.8% | -1439.8% | -486.9% | -331.5% | -521.6% | -24.5% | -656.2% |
| Return on Equity | -141.2%-214.1pp | 72.9%+994.5pp | -921.6%-498.1pp | -423.5%-332.8pp | -90.7%-2.7pp | -88.0%-30.1pp | -57.9%-53.7pp | -4.2%+240.2pp | -244.3% |
| Return on Assets | -105.7%-171.8pp | 66.1%+293.5pp | -227.4%+23.8pp | -251.2%-183.1pp | -68.1%-4.4pp | -63.7%-19.0pp | -44.8%-40.9pp | -3.9% | N/A |
| Current Ratio | 1.40-3.0x | 4.42+3.0x | 1.46-0.9x | 2.39-2.9x | 5.31-0.1x | 5.38-0.3x | 5.70-12.4x | 18.06 | N/A |
| Debt-to-Equity | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.00 | N/A |
| Liabilities-to-Equity | 0.34+0.2x | 0.10-2.9x | 3.05+2.4x | 0.69+0.4x | 0.33-0.1x | 0.38+0.1x | 0.29+0.2x | 0.08 | N/A |
| Asset Turnover | 0.030.0x | 0.04-0.3x | 0.35+0.2x | 0.170.0x | 0.14-0.1x | 0.19+0.1x | 0.09-0.1x | 0.16 | N/A |
| FCF Margin | -1256.0% | -1310.8% | -494.6% | -1137.6% | -467.3% | -315.5% | -335.6% | 26.0% | -428.2% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Addex Therapeutics Ltd ADXN | FY2025 | $218K | -$8.5M | N/A | $5.1M | — |
| Acurx Pharmaceuticals, Inc. ACXP | FY2025 | N/A | -$8.0M | N/A | $5.3M | — |
| Processa Pharmaceuticals, Inc. PCSA | FY2025 | N/A | -$13.6M | N/A | $5.1M | — |
| Can-Fite BioPharma Ltd. CANF | FY2025 | $405K | -$9.8M | N/A | $4.9M | — |
| Xenetic Biosciences, Inc. XBIO | FY2025 | $3.0M | -$2.7M | -90.1% | $4.4M | 66/100 |
| Longeveron Inc. LGVN | FY2025 | $1.2M | -$22.7M | N/A | $5.5M | 54/100 |
Where Addex Therapeutics Ltd Ranks
Frequently Asked Questions
Addex Therapeutics Ltd (ADXN) reported $218K in total revenue for fiscal year 2025. This represents a -51.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Addex Therapeutics Ltd (ADXN) revenue declined by 51.8% year-over-year, from $452K to $218K in fiscal year 2025.
No, Addex Therapeutics Ltd (ADXN) reported a net loss of $8.5M in fiscal year 2025.
As of fiscal year 2025, Addex Therapeutics Ltd (ADXN) had $2.1M in cash and equivalents against $0 in long-term debt.
Addex Therapeutics Ltd (ADXN) has a return on equity of -141.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Addex Therapeutics Ltd (ADXN) recorded an outflow of $2.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Addex Therapeutics Ltd (ADXN) recorded an outflow of $2.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Addex Therapeutics Ltd (ADXN) had $8.0M in total assets as of fiscal year 2025, including both current and long-term assets.
Addex Therapeutics Ltd (ADXN) reported no capital expenditure during fiscal year 2025.
Addex Therapeutics Ltd (ADXN) invested $846K in research and development during fiscal year 2025.
Addex Therapeutics Ltd (ADXN) had a current ratio of 1.40 as of fiscal year 2025, which is considered adequate.
Addex Therapeutics Ltd (ADXN) had a debt-to-equity ratio of 0.00 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Addex Therapeutics Ltd (ADXN) had a liabilities-to-equity ratio of 0.34 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Addex Therapeutics Ltd (ADXN) had a return on assets of -105.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Addex Therapeutics Ltd (ADXN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $5.1M as of Nov 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Addex Therapeutics Ltd (ADXN) trades at 23.3x sales, its market capitalization divided by $218K revenue, FY2025. The market capitalization is $5.1M as of Nov 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Addex Therapeutics Ltd (ADXN) has an Altman Z-Score of -79.04, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Addex Therapeutics Ltd (ADXN) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Addex Therapeutics Ltd (ADXN) reported a net loss of $8.5M while operations used $2.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Addex Therapeutics Ltd (ADXN) reported an operating loss of $3.5M against $614 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.